Magnetic glutathione-ferroferric oxide nano-particles, preparation method thereof and application of magnetic glutathione-ferroferric oxide nano-particles in enrichment of low-abundance protein in plasma
By coupling carboxylated iron tetraoxide nanoparticles with reduced glutathione to form magnetic glutathione-ferrooxide nanoparticles, the stability of nanoparticles in the biological environment and low plasma abundance is solved. Protein detection difficulties achieve efficient enrichment and separation of plasma proteins, improving the specificity and accuracy of detection.
Patent Information
- Application Number
- CN202411051554.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-01
- Publication Date
- 2024-11-08
AI Technical Summary
Existing iron tetraoxide nanoparticles are prone to interact with proteins in the biological environment to form protein crowns, affecting their biological response and stability. Moreover, low-abundance proteins in plasma are difficult to detect effectively and are easily interfered by high-abundance proteins.
Carboxylated iron tetraoxide nanoparticles and reduced glutathione are connected through amide bonds to form magnetic glutathione-ferrooxide nanoparticles for the enrichment and separation of plasma proteins, and through EDC-NHS couplets The reaction is combined and prepared under specific conditions to form a spherical particle structure with good dispersion and magnetic characteristics.
Effective enrichment and separation of low-abundance proteins in plasma is achieved, interference of high-abundance proteins is reduced, and the specificity and accuracy of detection is improved. It is suitable for the detection and prognosis of early disease markers.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] The invention relates to the field of functionalized magnetic nanoparticles, and in particular to magnetic glutathione-ferroferric oxide nanoparticles and a preparation method thereof and application thereof in enriching low-abundance proteins in plasma. Background Art
[0002] With the rapid development of nanotechnology, nanotechnology has become one of the most promising technologies in the 21st century. Nanoparticles have been widely used in biology, chemistry and daily consumer products. Due to the low toxicity, good biocompatibility and biodegradability, and the ability to undergo a variety of modifications, Fe3O4 nanoparticles (Fe3O4NPs) have broad application prospects in the medical field. Fe3O4NPs are mainly used in the medical field for drug carriers and gene delivery, biosensors, magnetic resonance imaging, contrast agents, hyperthermia, etc. It has been reported in the literature that when NPs enter the biological environment, they will interact with proteins, and the proteins in the environment will tend to bind to the surface of NPs, thereby forming a protein corona (PC). Current research results show that the PC formed on the surface of NPs will not only affect the biological response of NPs, including biodistribution, clearance and potential toxicity, but the composition of PC will also change with the disease state and specific disease conditions.
[0003] The trivalent Fe ions of ferroferric oxide nanoparticles (Fe3O4NPs) are randomly distributed in the octahedron and tetrahedron, while the divalent Fe ions are located in the center of the octahedron. At present, a variety of methods for preparing Fe3O4NPs have been developed, which are mainly divided into chemical methods and physical methods, among which chemical coprecipitation method and hydrothermal method are common synthesis methods. Due to their hydrophobic surface, Fe3O4NPs will interact with each other to form larger clusters, eventually forming larger particles and settling. In addition, the exposed Fe3O4NPs are usually highly chemically active and easier to be oxidized, but the magnetic properties are significantly weakened after oxidation. Therefore, surface functionalization modification is generally used to improve the water solubility, biocompatibility and stability of Fe3O4NPs, and promote their better application in the human body.
[0004] Biomarkers in blood exist in complex blood and their content is extremely low. Direct detection and analysis of patients' blood is easily interfered by other high-abundance proteins and will produce a higher response, thereby masking the signal of potential markers. Therefore, it is of great significance to develop blood-specific enrichment materials for separation before mass spectrometry analysis.
[0005] In view of this, the inventors prepared a new magnetic material Fe3O4-GSH NPs based on carboxylated ferroferric oxide nanoparticles for subsequent enrichment and separation tests in plasma proteins. Summary of the invention
[0006] The purpose of the present invention is to overcome the technical problems existing in the prior art, provide a magnetic glutathione-ferroferric oxide nanoparticle, provide a preparation method thereof, and provide its application in enrichment and separation test of plasma protein.
[0007] To achieve the above object, the technical solution adopted by the present invention is: On the one hand, the present invention provides a magnetic glutathione-ferroferric oxide nanoparticle, which uses carboxylated ferroferric oxide nanoparticles as cores and utilizes carboxyl groups to condense with amino groups of reduced glutathione to form amide bonds to form a spherical particle structure. The quantum dot size is 11.77 ± 2.12 nm and the surface zeta potential is -1.44 mv.
[0008] As a further improvement of the present invention, it includes: using carboxylated ferrosoferric oxide nanoparticles and reduced glutathione as reactants, coupling using EDC-NHS to obtain the glutathione-ferrosoferric oxide nanoparticles.
[0009] As a further improvement of the present invention, the following steps are specifically included: S1: Take the Fe3O4-COOH NPs preparation and add it to the MES activation buffer with a pH of 5.5-6.5, then add the EDC solution and NHS powder in sequence, stir at 20-25 °C for 1.5-2.5 h, wash with MES buffer, and redisperse in PBS solution; S2: Add L-GSH powder, stir and react for 11-13 hours, wash with PBS and redisperse to obtain.
[0010] As a further improvement of the present invention, in step S1, the molar ratio of the surface carboxyl groups of Fe3O4-COOH NPs to EDC is 1:1.2-1.5, and the molar ratio of EDC to NHS is 10:1.
[0011] As a further improvement of the present invention, the molar ratio of L-GSH to the Fe3O4-COOH NPs in step S2 is 1:10.
[0012] As a further improvement of the present invention, the Fe3O4-COOH NPs preparation is a 1% (w / v) PBS preparation.
[0013] As a further improvement of the present invention, the final concentration of the MES activation buffer is 0.05 M MES, and the volume ratio of the Fe3O4-COOH NPs preparation to the MES activation buffer is 4:1.
[0014] As a further improvement of the present invention, the process of washing and re-dispersing with PBS in step S2 is: after adsorbing NPs with a magnetic separation rack, repeatedly blowing and re-adsorbing with a pipette, and then re-dispersing the NPs in a PBS solution by ice bath ultrasound for 10-15 min.
[0015] In another aspect, the present invention provides the use of the magnetic glutathione-ferroferric oxide nanoparticles in the enrichment and separation test of plasma proteins.
[0016] As a further improvement of the present invention, the plasma protein is a low-abundance plasma protein.
[0017] The “low abundance” mentioned in the present invention generally refers to less than 10 ng / mL.
[0018] The beneficial effects of adopting the above technical solution are: 1. The glutathione-ferroferric oxide nanoparticles provided by the present invention have the characteristics of good dispersibility, obvious magnetic characteristics and not easy to agglomerate.
[0019] 2. The preparation method provided by the present invention has the characteristics of simple operation, low cost, short preparation cycle and suitability for popularization and application.
[0020] 3. The glutathione-ferroferric oxide nanoparticles provided by the present invention have low toxicity and a strong protein enrichment effect. They can be used as protein enrichers to solve the problem that it is difficult to detect trace proteins in the current plasma proteome, thereby combining the LC-MS / MS method to identify trace proteins, thereby discovering potential markers to improve early detection or prognosis. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 is a diagram of the mechanism of carboxyl activation by EDC-NHS in Example 1; Figure 2 is a flow chart of L-GSH functionalization of Fe3O4-COOH NPs and separation in Example 1; Figure 3 is the microscopic image and particle size distribution diagram of Fe3O4-COOH NPs observed by TEM in Example 1; Figure 4 The Fe3O4-GSH NPs obtained in Example 1 are in the presence (left) and absence (right) of an external magnetic field; Figure 5It is the hard protein corona after the Fe3O4-GSH NPs obtained by reacting with EDC:NHS=10:1 in Example 2 and combining with plasma; Figure 6 is the SDS-PAGE result of the Fe3O4-GSH NPs surface binding kinetics in Example 2; Figure 7 is a comparison chart of the protein enrichment of Fe3O4-GSH NPs and the content of plasma protein in Example 2; Figure 8 is a bar graph of the GRAVY value of Fe3O4-GSH NPs enriched to proteins in Example 2; Fig. 9 is a bar graph showing the molecular weight of proteins enriched by Fe3O4-GSH NPs in Example 2; Fig.10 It is the interaction network analysis of the proteins identified by HPC after co-incubation of healthy human plasma with Fe3O4-GSH NPs and the ClueGO enrichment analysis diagram of the biological processes and pathways of the enriched proteins. DETAILED DESCRIPTION
[0022] In order to make the objectives, technical solutions and advantages of the present invention more clear, the present invention is clearly and completely described below in conjunction with specific embodiments.
[0023] Unless otherwise specified, the reagents used in this embodiment are all conventional reagents and the operations are all conventional operations. In this embodiment, Fe3O4-COOH NPs were purchased from Tianjin Bestle Biotechnology Co., Ltd., model Affimag FEO No. 3612.
[0024] The glutathione-ferroferric oxide coupled nanocomposite (Fe3O4-GSH NPs) of the present invention is formed by the amide bond connection between reduced glutathione and ferroferric oxide nanoparticles through EDC-NHS reaction. The reaction mechanism is shown in FIG. Figure 1 The process of synthesizing L-GSH functionalized Fe3O4-GSH NPs and incubating with plasma and separating them is shown in Figure 2 shown.
[0025] Example 1 Preparation of glutathione-ferroferric oxide nanocomposite S1: Activation of carboxylated FeO particles First, prepare MES activation buffer with a final concentration of 0.05 M MES, and adjust the pH to 6.0 with NaOH. Take 400 μl of PBS preparation containing 1% (w / v) Fe3O4-COOH NPs, and then add 100 μl MES activation buffer with pH 6.0, 500 μl EDC, and 22 mg NHS powder (EDC and NHS molar ratio is 10:1) in sequence. Mix the reaction at 25°C with a stirring paddle at 800 rpm for 2 h, wash three times with MES buffer, and redisperse in PBS solution.
[0026] S2: Conjugation of L-GSH 200 mg of L-GSH powder was added to the above-dispersed PBS solution, reacted at 800 rpm for 12 h, and then washed with PBS and redispersed. The washing process was to adsorb NPs using a magnetic separation rack, re-adsorb them by repeated blowing with a pipette, and then redisperse NPs in the PBS solution by ice bath ultrasound for 10 min.
[0027] Characterization of Fe3O4-GSH NPs: Take an appropriate amount of Fe3O4-GSH NPs, resuspend them with ultrapure water, and then ultrasonicate them in an ice bath for 10 min to make them evenly dispersed. Use a 10μl pipette to gently drop a drop of Fe3O4-GSH NPs suspension on a copper grid, dry it naturally at room temperature, and observe the morphology and particle size distribution of Fe3O4-GSH NPs using TEM. Use Nano measurer 1.2 software to randomly measure the particle size of 100 Fe3O4-GSH NPs and obtain the average particle size of each Fe3O4-GSH NP. The morphology, particle size and dispersion of the prepared magnetic nanomaterials can be observed and analyzed by electron microscopy.
[0028] The results are as follows Figure 3 As shown in Figure 2, the morphology of the magnetic nanomaterial Fe3O4-GSH NPs was observed by transmission electron microscopy (TEM). Figure 3 As shown in (a) to (b), the prepared Fe3O4-GSH NPs nanomaterials have a smooth and flat surface and present uniform, spherical particles. Figure 3 (c) The particle distribution in the image was analyzed using Nano measurer 1.2 software, and the average particle size of Fe3O4-GSH NPs was measured to be 11.77 ± 2.12 nm. Figure 3(d) shows the particle size distribution of Fe3O4-GSH NPs. It can be seen that the synthesized Fe3O4-GSH NPs are well dispersed and have uniform particle size without obvious agglomeration. Since the bound reduced glutathione is a short peptide of 3 amino acids, the particle size of the nanoparticles does not change significantly, which is in line with theoretical expectations.
[0029] Example 2 1. Preparation of Rat Plasma and Collection of Patient Plasma A total of 5 SD rats were used. Before all sampling operations, the rats were weighed, anesthetized with 2-3% isoflurane inhalation, their beards and eyelashes were cut to avoid hemolysis, and the inner canthus of the eye was punctured with a capillary. When taking blood from the inner canthus, the skin between the two ears of the rat was grasped to fix its head, and the neck was gently pressed on both sides to make the eyeball fully protrude and the posterior venous plexus congested. The capillary was held and rotated to insert it into the inner canthus blood vessel. The blood flowed into the EDTA anticoagulation tube due to blood pressure. After the capillary was pulled out, the hand pressing the rat was relaxed. To prevent bleeding from the puncture hole, cotton balls can be used to press the bleeding part of the eyeball to achieve the purpose of hemostasis. 0.5 ml of blood can be collected from rats at a time, and the total blood collection volume for a single rat is 1 ml. The collected plasma was centrifuged at 2000 g, 10 min, and 4°C. The light yellow supernatant was taken and divided into 100 μl per tube and frozen in a -80°C refrigerator.
[0030] 2. Incubation and separation of Fe3O4-GSH NPs and plasma To investigate the enrichment effect and specificity of magnetic nanomaterials, 100 μl of Fe3O4-GSH NPs (with Fe as the base concentration of 4 mg / ml, the solvent was PBS solution, pH = 7.4) and 100 μl of plasma were taken and incubated in a thermostatic oscillator at 1400 rpm, 37°C, for 12 h. After incubation, the particles were centrifuged at 15000 g, 17000 g, and 19000 g. After each centrifugation, the particles were collected and transferred to a preparation with a soft protein corona (PC). The soft PC was then removed so that only HPC was retained by applying centrifugation cycles in different washing solutions, where the washing solutions were 50 mM and 100 mM NaCl solutions, respectively. Finally, 20 μl of the preparation containing HPC was aspirated, 5 μl of 5 × loading buffer was added, and ultrasonication was performed for 5 min to release the peptides and proteins bound to the nanoparticles. Heat at 95°C for 10 min and centrifuge for 1 min.
[0031] The results of incubation and separation of enriched proteins are shown in Figure 5 , Figure 6 shown. Figure 5The SDS-PAGE image of Fe3O4-GSH NPs protein binding. The carboxyl group was activated at a ratio of EDC:NHS = 10:1. 50mm is 50mm NaCl solution; 100mm is 100mm NaCl solution; HPC (Hard protein corona) is a constant protein corona; -1 and -2 are two parallel experiments. Figure 5 It can be observed that the band at 100 kDa is obvious after the reaction with EDC:NHS=10:1, indicating that the amount of protein with a molecular weight of ~100 kDa is large; and there are also bands at 50-70 kDa that are different from the plasma protein band. Combined with the PDI results measured by the Malvern particle size analyzer, its dispersibility has been optimized, and PDI has been reduced from 1.0 to 0.21. Therefore, the Fe3O4-GSH NPs prepared with EDC:NHS = 10:1 reduced the aggregation of magnetic materials and improved the enrichment performance of PC.
[0032] Figure 6 The SDS-PAGE image of the binding dynamics on the surface of Fe3O4-GSH NPs. Among them, 50mm is 50mm NaCl solution; 100mm is 100mm NaCl solution; HPC (Hard protein corona) is hard protein corona; -R (rat) means incubation with rat plasma, and -H (human) means incubation with human plasma. From the PR and PH lanes in the figure, it can be observed that the human plasma protein content is higher; and it can be observed that when eluted with 50 mM NaCl solution, there is a small amount of protein in both groups, but after elution with 100 mM NaCl solution, it can be seen that there is almost no protein in the 100 mM-R and 100 mM-H lanes, and only a very small amount of 70kDa molecular weight protein exists. It can be considered that the separation method of high-speed centrifugation is also applicable to healthy human plasma. There were also significant differences in the HPC-R and HPC-H bands incubated with rat plasma and healthy human plasma, and compared with the plasma bands without the addition of Fe3O4-GSH NPs, different enrichment-specific bands were obtained, as shown by the arrows.
[0033] 3. Identification of plasma-specific enriched proteins 3.1 Preparation of SDS-polyacrylamide gel 1) Select a 1.5 cm glass plate and use Liquinox phosphoric acid-free liquid detergent to clean it to remove the residual rubber particles on the surface of the glass plate.
[0034] 2) Install the glass plate on the glue dispensing device and secure it firmly to prevent leakage from the bottom.
[0035] 3) Leak test: Fill the space between the two fixed glass plates with pure water and let it stand for a few minutes. If the liquid level does not drop, it means the seal is good. After confirming that there is no leakage, use filter paper to absorb the water.
[0036] 4) Prepare 10% separation gel with 4000 μl ultrapure water, 3300 μl 30% acrylamide, 2500 μl 1.5M Tris (pH=8.8), 100 μl 10% SDS, 100 μl 10% ammonium persulfate (AP) and 10 μl TEMED. Vortex to mix well and immediately inject it between the two glass plates with a pipette (to a distance of 0.5 cm from the lower edge of the green plate at the back). After adding the separation gel, immediately fill the upper layer of the separation gel with anhydrous ethanol and let it stand at room temperature until a clear refractive line appears at the interface between the anhydrous ethanol and the separation gel.
[0037] 5) Pouring concentrated gel: Pour off the anhydrous ethanol, tilt the gel-making device and use filter paper to absorb the remaining liquid.
[0038] Prepare 5% SDS-PAGE stacking gel (pre-prepared volume is 5 ml, two plates of gel) with 3420 μl ultrapure water, 830 μl 30% acrylamide, 625 μl 1.0M Tris (pH = 6.8), 50 μl 10% SDS, 75 μl 10% ammonium persulfate (AP) and 7.5 μl TEMED, vortex to mix, and slowly fill the stacking gel with a pipette to prevent bubbles. After adding the stacking gel, quickly insert a 15-hole ruler into the gel layer. The gel will completely solidify about 40-60 minutes after preparation.
[0039] 6) Sample preparation: The loading buffer used in the experiment is 5× loading buffer, protein 10-30 μg. Add 20 μl of HPC sample and 5 μl loading buffer.
[0040] 7) Gel electrophoresis: Remove the glass interlayer, place the glass interlayer on one side and the baffle on the other side, fix them in the electrophoresis tank, pull out the ruler comb with force while balancing upwards, and the sample well will appear. Fill the electrophoresis tank with electrophoresis buffer (pre-prepared volume is 1000 ml, Tris 3.02 g, Glycine 18.76 g, SDS1.00 g). Use a pipette to slowly add 10 μl of sample and 2.5 μl of marker to the sample well in the following order. Place the electrophoresis tank into the electrophoresis tank and add an appropriate amount of electrophoresis solution to the electrophoresis tank. Connect the power supply, run the electrophoresis at 80V to the boundary between the separation gel and the concentrated gel, then switch to 120V for about 40 min.
[0041] 8) Coomassie Brilliant Blue Staining Use a gel opener to pry up the glass plate, remove the gel from the sandwich, and place it in a 10 cm glass dish. Wash the gel with 20 ml of cleaning solution (8 ml water + 10 ml methanol + 2 ml acetic acid) for 10 min. Stain with 20 ml of Coomassie Brilliant Blue staining solution for 50 min; decolorize with 20 ml of deionized water for 10 min, and replace with clean deionized water.
[0042] 3.2 In-gel digestion The electrophoresis gel obtained by SDS-PAGE gel electrophoresis can only show the protein distribution. In order to further identify the type and quantity of the protein, it is necessary to digest the protein in the gel by in-gel enzyme cutting and identify it by mass spectrometry technology.
[0043] 1) Use a gel opener to transfer the gel to the surface of a 10 cm glass culture dish, and use a disposable scalpel to remove unnecessary parts such as the top, bottom, and marker, leaving only the part related to the target protein. Cut each strip into 1×1 mm 2 Use the same blade to transfer the small gel pieces to a 1.5 ml low-absorption centrifuge tube.
[0044] 2) Add 300 μl of water, 100% acetonitrile and 100 mM NH4HCO3 to wash the gel for 15 min each and discard the supernatant.
[0045] 3) Add 300 μl of a mixed solution of 100 mM NH4HCO3 and CH3CN ( V: V = 1:1) to wash the gel for 15 min and discard the supernatant.
[0046] 4) Add 100 μl CH3CN to dry the gel for 5 min, discard the supernatant, and evaporate the sample at room temperature for 5 min to remove excess CH3CN.
[0047] 5) Reductive alkylation. The following washing and incubation operations were performed in a thermostatic mixer at 1500 rpm and 25°C. Add 50 μl of 10 mM DTT to each tube and incubate at 37°C for 1 h. After discarding the supernatant, add 50 μl of 50 mM IAM to each tube and incubate at 25°C in the dark for 30 min. Discard the supernatant. Add 300 μl of 100 mM NH4HCO3 to wash the gel for 15 min and discard the supernatant. Add 300 μl of a mixed solution of 20 mM NH4HCO3 and CH3CN ( V: V = 1:1) Wash the gel block for 15 min and discard the supernatant. Add 100 μl CH3CN to dry the gel block for 5 min and discard the supernatant. Volatilize the sample at room temperature for 5 min to evaporate the excess CH3CN. 3.3 Enzymatic hydrolysis Add 20 μl of 10 ng / μl trypsin digestion solution to each tube and swell at 4°C for 1 h. Then incubate at 37°C for 12 h.
[0048] 3.4 Peptide extraction Add an equal volume of CH3CN to the enzyme digestion system and incubate at 37℃ for 30 min. Transfer the supernatant to a new low-adsorption centrifuge tube. Add 50 μl of 1% formic acid water to the gel block, incubate at 25℃ for 20 min, and transfer the supernatant to the above centrifuge tube. Repeat the addition of formic acid water once and perform the same operation as above. Add 150 μl of CH3CN to the gel block, incubate at 25℃ for 10 min, and transfer the supernatant to the above centrifuge tube. Vacuum dry the liquid in the centrifuge tube to make it completely dry.
[0049] 3.5 Mass spectrometry The sample was reconstituted with 1% formic acid, centrifuged at 15,000 × g, 4°C for 10 min, and the supernatant was aspirated into a sample vial.
[0050] 4. Nano LC-MS / MS Detection The samples were reconstituted with 10 µL of 0.1% formic acid aqueous solution, vortexed for 3 min, centrifuged on a palmtop and then sonicated for 2 min, centrifuged at 15,000 g for 10 min, and the supernatant was transferred to an injection vial, which was placed in the sample tray of the Easy-nLC 1000 nanoliter liquid chromatograph.
[0051] 5. Chromatographic conditions: Chromatographic column: laboratory-made capillary column (75 µm × 165 mm), filler C 18 Resin (3 µm, Aqua C 18 , Phenomenex , USA); mobile phase A was an aqueous solution containing 0.1% formic acid; mobile phase B was an acetonitrile solution containing 0.1% formic acid. The gradient of mobile phase B was: 0 ~ 1 min: 5% ~ 7%; 1 ~ 71 min: 7% ~ 26%; 71 ~ 81 min: 26% ~ 60%; 81 ~ 82 min: 60% ~ 95%; 82 ~ 90 min: 95%.
[0052] Injection volume: 3 µL; Loading volume: 8 µL; Loading flow rate: 20 µL / min; Equilibration volume: 5 µL; Flow rate: 0.3 µL / min; Column temperature: 50°C.
[0053] 6. Mass spectrometry conditions Ion source: NSI electrospray source; spray voltage: positive ion, 2000 V; ion transfer tube temperature: 300°C; RF-lens: 60%; cycle time: 3 s; dynamic exclusion time: 40 s.
[0054] Primary scanning parameters: Mass analyzer: Orbitrap; Scan range (mass-to-charge ratio, m / z): 350 ~ 1950; Resolution: 60000 Hz; Maximum injection time: 50 ms; Automatic gain control (AGC): 2.0 e5 .Secondary scanning parameters: Isolation mode: quadrupole; Resolution: 15000 Hz; Maximum injection time: 100 ms; AGC: 1.0 e5 ; Fragmentation mode and energy: high-energy collision dissociation (HCD), 38%.
[0055] 7. Mass Spectrometry Data Analysis Maxquant software was used to search and identify the collected raw files. Search engine: Andromeda; Database: Uniprot rat full protein database; Protease: Trypsin (full); Precision of parent ion mass: 15 ppm; Maximum missed cleavage site: 5.
[0056] 8. Proteomics Data Analysis After searching the library with Maxquant, protein identification information was obtained. The physicochemical properties of all proteins identified by proteomics of the protein corona enriched with Fe3O4-GSH NPs in rat plasma were investigated from five aspects: protein molecular weight (MW), sequence coverage, number of unique peptides, label free quantitation (LFQ) value, and enrichment ratio. The molecular weight, sequence coverage, number of unique peptides, and LFQ values can be obtained based on the Maxquant software search results as follows: Figure 7 , Figure 8 and Fig. 9 The protein enrichment multiple can be obtained by calculating the LFQ value of the protein contained in the protein corona and the LFQ value of plasma and blank internal reference. The final bioinformatics results are as follows: Fig.10 .
[0057] Figure 7The enrichment multiples of 46 proteins were displayed. Taking plasma protein as the standard, the ratio of the protein content after enrichment to the protein content in plasma was the enrichment multiple. It can be seen that there were about 8 proteins with enrichment ratios higher than 20 times, among which HABP2 had the highest enrichment ratio of 102.35 times.
[0058] Figure 8 The Gravy values of 46 enriched proteins are shown. The Gravy value is also called the average hydrophilicity, which is defined as the ratio of the sum of the hydrophilicity values of all amino acids in the sequence to the number of amino acids. The larger the negative value, the better the hydrophilicity, and the larger the positive value, the stronger the hydrophobicity. Figure 8 As shown, most of the proteins enriched by Fe3O4-GSH NPs are hydrophilic and easier to bind tightly to the surface of NPs to form a protein corona.
[0059] Fig. 9 The molecular weight differences of 46 proteins are shown, and it can be seen that they are mainly distributed in the range of 50-100kDa and 25kDa. Figure 6 As shown, proteins enriched by Fe3O4-GSH NPs can avoid the masking effect of high-abundance protein signals and identify low-abundance proteins.
[0060] The enriched proteins of 46 HPCs in plasma were analyzed using the STRING online platform, and the analysis results were imported into Cytoscape for visualization ( Fig.10 - a), among which RAB7A, HSPA8, and ANXA2 have the highest degree values and are key proteins in the protein-protein interaction network. In order to better understand the biological processes and pathways involved in the plasma proteins enriched by Fe3O4-GSH NPs, the ClueGO plug-in of Cytoscape was used to perform GO-BP, GO-CC, GO-MF, and KEGG pathway analysis on the 46 enriched proteins ( Fig.10 -b).
[0061] Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art may still modify the technical solutions described in the aforementioned embodiments, or make equivalent substitutions for some of the technical features therein; and these modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims
1. A magnetic glutathione-ferroferric oxide nanoparticle, characterized in that: It uses carboxylated ferroferric oxide nanoparticles as the core, and uses the carboxyl group to condense with the amino group of reduced glutathione to form an amide bond to form a spherical particle structure. The quantum dot size is 11.77 ± 2.12 nm and the surface zeta potential is -1.44 mv.
2. A method for preparing magnetic glutathione-ferroferric oxide nanoparticles as claimed in claim 1, characterized in that: It includes: Carboxylated ferroferric oxide nanoparticles and reduced glutathione are used as reactants and coupled by using EDC-NHS to obtain the glutathione-ferroferric oxide nanoparticles.
3. The method for preparing magnetic glutathione-ferroferric oxide nanoparticles according to claim 2, characterized in that: The specific steps include: S1: Take the carboxylated ferroferric oxide nano Fe3O4-COOH NPs preparation and add it to the MES activation buffer with a pH of 5.5-6.5, then add the EDC solution and NHS powder in sequence, stir at 20-25°C for 1.5-2.5 h, wash with MES buffer, and redisperse in PBS solution; S2: Add L-GSH powder, stir and react for 11-13 hours, wash with PBS and redisperse to obtain.
4. The method for preparing magnetic glutathione-ferroferric oxide nanoparticles according to claim 3, characterized in that: In the step S1, the molar ratio of the surface carboxyl groups of Fe3O4-COOH NPs to EDC is 1:1.2-1.5, and the molar ratio of EDC to NHS is 10:
1.
5. The method for preparing magnetic glutathione-ferroferric oxide nanoparticles according to claim 3, characterized in that: The molar ratio of L-GSH to the Fe3O4-COOH NPs in the step S2 is 1:
10.
6. The method for preparing magnetic glutathione-ferroferric oxide nanoparticles according to claim 3, characterized in that: The Fe3O4-COOH NPs preparation was a 1% (w / v) PBS preparation.
7. The method for preparing magnetic glutathione-ferroferric oxide nanoparticles according to claim 3, characterized in that: The final concentration of the MES activation buffer was 0.05 M MES, and the volume ratio of the Fe3O4-COOH NPs preparation to the MES activation buffer was 4:
1.
8. The method for preparing magnetic glutathione-ferroferric oxide nanoparticles according to claim 3, characterized in that: The process of washing and re-dispersing with PBS in step S2 is as follows: after the NPs are adsorbed by a magnetic separation rack, they are re-adsorbed by repeated blowing with a pipette, and then the NPs are re-dispersed in a PBS solution by ice bath ultrasound for 10-15 min.
9. Use of the magnetic glutathione-ferroferric oxide nanoparticles as claimed in claim 1 in enrichment and separation of plasma proteins.
10. The use according to claim 9, characterized in that: The plasma protein is a low-abundance plasma protein.
